298 related articles for article (PubMed ID: 31040112)
21. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
22. Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Zhou L; Fu L; Lv N; Liu J; Li Y; Chen X; Xu Q; Chen G; Pang B; Wang L; Li Y; Zhang X; Yu L
Exp Mol Med; 2018 Apr; 50(4):1-8. PubMed ID: 29674693
[TBL] [Abstract][Full Text] [Related]
23. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract][Full Text] [Related]
24. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
26. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
27. Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
Chen D; Chen W
Br J Haematol; 2021 May; 193(4):691. PubMed ID: 33386742
[No Abstract] [Full Text] [Related]
28. Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.
Jakobczyk H; Debaize L; Soubise B; Avner S; Rouger-Gaudichon J; Commet S; Jiang Y; Sérandour AA; Rio AG; Carroll JS; Wichmann C; Lie-A-Ling M; Lacaud G; Corcos L; Salbert G; Galibert MD; Gandemer V; Troadec MB
J Hematol Oncol; 2021 Mar; 14(1):47. PubMed ID: 33743795
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
[TBL] [Abstract][Full Text] [Related]
30. The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.
Yan JS; Li YD; Liu SH; Yin QQ; Liu XY; Xia L; Lu Y
Leuk Lymphoma; 2017 Aug; 58(8):1985-1988. PubMed ID: 28092997
[No Abstract] [Full Text] [Related]
31. Detection of rare reciprocal RUNX1 rearrangements by next-generation sequencing in acute myeloid leukemia.
Flach J; Shumilov E; Joncourt R; Porret N; Tchinda J; Legros M; Scarpelli I; Hewer E; Novak U; Schoumans J; Bacher U; Pabst T
Genes Chromosomes Cancer; 2020 Apr; 59(4):268-274. PubMed ID: 31756777
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
[TBL] [Abstract][Full Text] [Related]
34. Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia.
Qin YZ; Wang Y; Xu LP; Zhang XH; Zhao XS; Liu KY; Huang XJ
J Mol Diagn; 2020 Feb; 22(2):188-195. PubMed ID: 31751675
[TBL] [Abstract][Full Text] [Related]
35. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
36. Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules.
Kondo H; Kanayama T; Matsumura U; Urata T; Osone S; Imamura T; Inaba T; Hosoi H
Int J Hematol; 2021 May; 113(5):616-617. PubMed ID: 33782817
[No Abstract] [Full Text] [Related]
37. The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter.
Chen G; Liu A; Xu Y; Gao L; Jiang M; Li Y; Lv N; Zhou L; Wang L; Yu L; Li Y
FEBS J; 2019 Mar; 286(5):901-912. PubMed ID: 30637949
[TBL] [Abstract][Full Text] [Related]
38. Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo.
Neldeborg S; Soerensen JF; Møller CT; Bill M; Gao Z; Bak RO; Holm K; Sorensen B; Nyegaard M; Luo Y; Hokland P; Stougaard M; Ludvigsen M; Holm CK
Leukemia; 2023 Sep; 37(9):1792-1801. PubMed ID: 37464068
[TBL] [Abstract][Full Text] [Related]
39. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer.
Tian Y; Wang G; Hu Q; Xiao X; Chen S
J Cell Biochem; 2018 Apr; 119(4):3706-3715. PubMed ID: 29236325
[TBL] [Abstract][Full Text] [Related]
40. GFI1 is required for
Marneth AE; Botezatu L; Hönes JM; Israël JCL; Schütte J; Vassen L; Lams RF; Bergevoet SM; Groothuis L; Mandoli A; Martens JHA; Huls G; Jansen JH; Dührsen U; Berg T; Möröy T; Wichmann C; Lo MC; Zhang DE; van der Reijden BA; Khandanpour C
Haematologica; 2018 Sep; 103(9):e395-e399. PubMed ID: 29674496
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
